Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 4:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,622 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
ABT-751 and Carboplatin
Drug
Lead sponsor
Konstantin Dragnev
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
Interventions
Epacadostat, Atezolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795
Conditions
Non Small-cell Lung Cancer
Interventions
Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
Interventions
PF-08046052
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Los Angeles, California • Santa Monica, California • Tampa, Florida + 10 more
Conditions
Non Small Cell Lung Cancer
Interventions
RAD001, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
Drug
Lead sponsor
Brown University
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating tumor cell chip
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Conditions
Stage III Non-small-cell Lung Cancer
Interventions
Durvalumab
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Recruiting Phase 1 Interventional

DK222 Study at Hopkins

NCT07140315
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
[18F]DK222 radiotracer
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Lung Cancer
Interventions
carboplatin, erlotinib hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
124
States / cities
Little Rock, Arkansas • Antioch, California • Berkeley, California + 90 more
Conditions
Non-Small Cell Lung Cancer - Completely Resectable
Interventions
L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Biological
Lead sponsor
AVAX Technologies
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Fayetteville, Arkansas • Philadelphia, Pennsylvania
Conditions
Carcinoma, Non Small Cell Lung
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
19
States / cities
Duarte, California • Pasadena, California • South Pasadena, California + 6 more
Conditions
Solid Tumor
Interventions
Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin, 5-fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Lake Success, New York • Nashville, Tennessee • Fairfax, Virginia
Conditions
Neoplasms
Interventions
Qualitative Interviews, PROMIS Physical Function Items
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Conditions
Lung Cancer
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Terminated Phase 1Phase 2 Interventional Results available

Abraxane and Alimta in Advanced Solid Tumors

NCT00470548
Conditions
Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Abraxane, Alimta
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Sacramento, California
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab with chemotherapy, Pleur-XTM catheter placement
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Non Small Cell Lung Cancer
Interventions
CMP-001, Atezolizumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Gilbert, Arizona • Duarte, California • Aurora, Colorado + 2 more
Conditions
Non Small Cell Lung Cancer
Interventions
Tulmimetostat
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Long Beach, California • Sacramento, California • San Diego, California + 2 more
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
ARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
13
States / cities
Stanford, California • Washington D.C., District of Columbia • Weston, Florida + 10 more
Active, not recruiting No phase listed Observational

MYLUNG Consortium Study Protocol 2

NCT05644808
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Daphne, Alabama • Denver, Colorado • Pensacola, Florida + 14 more